A novel molecular therapy using bioengineered adenovirus for human gastrointestinal cancer

Acta Medica Okayama

Volumn 65, Issue 3, 2011, Pages 151-162

  Fujiwara, Toshiyoshi ^a  

^a OKAYAMA UNIVERSITY   (Japan)

Author keywords

Adenovirus; Colorectal cancer; Lymph node; Metastasis; Telomerase

Indexed keywords

TELOMERASE; TERT PROTEIN, HUMAN;

ADENOVIRUS; ARTICLE; BIOENGINEERING; GASTROINTESTINAL TUMOR; GENE THERAPY; GENETICS; HUMAN; METABOLISM; PHYSIOLOGY; PROMOTER REGION;

ADENOVIRIDAE; BIOENGINEERING; GASTROINTESTINAL NEOPLASMS; GENE THERAPY; HUMANS; PROMOTER REGIONS, GENETIC; TELOMERASE;

ADENOVIRIDAE; HUMAN ADENOVIRUS TYPE 5;

EID: 79960120576     PISSN: 0386300X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (81)

1. Kaplan JM: Adenovirus-based cancer gene therapy. Curr Gene Ther (2005) 5: 595-605.
2. Guo ZS, Thome SH and Bartlett DL: Oncolytic virotherapy: molecular targets in tumor-selective replication and carrier cell-mediated delivery of oncolytic viruses. Biochim Biophys Acta (2008) 1785: 217-231.
3. Kirn DH and Thome SH: Targeted and armed oncolytic poxviruses: a novel multi-mechanistic therapeutic class for cancer. Nat Rev Cancer (2009) 9: 64-71.
4. Mizuguchi H and Kay MA: Efficient construction of a recombinant adenovirus vector by an improved in vitro ligation method. Hum Gene Ther (1998) 9: 2577-2583.
5. Stone D and Lieber A: New serotypes of adenoviral vectors. Curr Opin Mol Ther (2006) 8: 423-431.
6. Wilson JM, Engelhardt JF, Grossman M, Simon RH and Yang Y: Gene therapy of cystic fibrosis lung disease using E1 deleted adenoviruses: a phase I trial. Hum Gene Ther (1994) 5: 501-519.
7. Crystal RG, McElvaney NG, Rosenfeld MA, Chu CS, Mastrangeli A, Hay JG, Brody SL, Jaffe HA, Eissa NT and Danel C: Administration of an adenovirus containing the human CFTR cDNA to the respiratory tract of individuals with cystic fibrosis. Nat Genet (1994)8: 42-51.
8. Crystal RG, Hirschowitz E, Lieberman M, Daly J, Kazam E, Henschke C, Yankelevitz D, Kemeny N, Silverstein R, Ohwada A, Russi T, Mastrangeli A, Sanders A, Cooke J and Harvey BG: Phase I study of direct administration of a replication deficient ade novirus vector containing the E. coli cytosine deaminase gene to metastatic colon carcinoma of the liver in association with the oral administration of the pro-drug 5-fluorocytosine. Hum Gene Ther (1997)8: 985-1001.
9. Sterman DH, Treat J, Litzky LA, Amin KM, Coonrod L, Molnar-Kimber K, Recio A, Knox L, Wilson JM, Albelda SM and Kaiser LR: Adenovirus-mediated herpes simplex virus thymidine kinase/ganciclovir gene therapy in patients with localized malignancy: results of a phase I clinical trial in malignant mesothelioma. Hum Gene Ther (1998) 9: 1083-1092.
10. Liu TC, Galanis E and Kirn D: Clinical trial results with oncolytic virotherapy: a century of promise, a decade of progress. Nat Clin Pract Oncol (2007) 4: 101-117.
11. Fujiwara T: Telomerase-specific virotherapy for human squamous cell carcinoma. Expert Opin Biol Ther (2009) 9: 321-329.
12. Hawkins LK, Lemoine NR and Kirn D: Oncolytic biotherapy: a novel therapeutic platform. Lancet Oncol (2002) 3: 17-26.
13. Bischoff JR, Kirn DH, Williams A, Heise C, Horn S, Muna M, Ng L, Nye JA, Sampson-Johannes A, Fattaey A and McCormick F: An adenovirus mutant that replicates selectively in p53-deficient human tumor cells. Science (1996) 274: 373-376.
14. Khuri FR, NemunaitisJ, Ganly I, Arseneau J, Tannock IF, Romel L, Gore M, Ironside J, MacDougall RH, Heise C, Randlev B, Gillenwater AM, Bruso P, Kaye SB, Hong WK and Kirn DH: A controlled trial of intratumoral ONYX-015, a selectively-replicating adenovirus, in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer. Nat Med (2000) 6: 879-885.
15. Nemunaitis J, Khuri F, Ganly I, Arseneau J, Posner M, Vokes E, KuhnJ, McCarty T, Landers S, Blackburn A, Romel L, Randlev B, Kaye S and Kirn D: Phase II trial of intratumoral administration of ONYX-015, a replication-selective adenovirus, in patients with refractory head and neck cancer. J Clin Oncol (2001) 19: 289-298.
16. Goodrum FD and Ornelles DA: p53 status does not determine out come of E1B 55-kilodalton mutant adenovirus lytic infection. J Virol (1998) 72: 9479-9490.
17. O'Shea CC, Johnson L, Bagus B, Choi S, Nicholas C, Shen A, Boyle L, Pandey K, Soria C, Kunich J, Shen Y, Habets G, Ginzinger D and McCormick F: Late viral RNA export, rather than p53 inactivation, determines ONYX-015 tumor selectivity. Cancer Cell (2004) 6: 611-623.
18. Shay JW and Bacchetti S: A survey of telomerase activity in human cancer. Eur J Cancer (1997) 33: 787-791.
19. Dong CK, Masutomi K and Hahn WC: Telomerase: regulation, function and transformation. Crit Rev Oncol Hematol (2005) 54: 85-93.
20. Hiyama K, Hirai Y, Kyoizumi S, Akiyama M, Hiyama E, Piatyszek MA, Shay JW, Ishioka S and Yamakido M: Activation of telom erase in human lymphocytes and hematopoietic progenitor cells. J Immunol (1995) 155: 3711-3715.
21. Tahara H, Yasui W, Tahara E, Fujimoto J, Ito K, Tamai K, Nakayama J, Ishikawa F, Tahara E and Ide T: Immunohistochemical detection of human telomerase catalytic component, hTERT, in human colorectal tumor and non-tumor tissue sections. Oncogene (1999) 18: 1561-1567.
22. Shay JW and Wright WE: Telomerase: a target for cancer thera peutics. Cancer Cell (2002) 2: 257-265.
23. Feng J, Funk WD, Wang SS, Weinrich SL, Avilion AA, Chiu CP, Adams RR, Chang E, Allsopp RC and Yu J: The RNA component of human telomerase. Science (1995) 269: 1236-1241.
24. Harrington L, McPhail T, Mar V, Zhou W, Oulton R, Bass MB, Arruda I and Robinson MO: A mammalian telomerase-associated protein. Science (1997) 275: 973-977.
25. Meyerson M, Counter CM, Eaton EN, Ellisen LW, Steiner P, Caddie SD, Ziaugra L, Beijersbergen RL, Davidoff MJ, Liu Q, Bacchetti S, Haber DA and Weinberg RA: hEST2, the putative human telomerase catalytic subunit gene, is up-regulated in tumor cells and during immortalization. Cell (1997) 90: 785-795.
26. Nakamura TM, Morin GB, Chapman KB, Weinrich SL, Andrews WH, Lingner J, Harley CB and Cech TR: Telomerase catalytic subunit homologs from fission yeast and human. Science (1997) 277: 955-959.
27. Nakayama J, Tahara H, Tahara E, Saito M, Ito K, Nakamura H, Nakanishi T, Tahara E, Ide T and Ishikawa F: Telomerase activa tion by hTRT in human normal fibroblasts and hepatocellular carci nomas. Nat Genet (1998) 18: 65-68.
28. Beattie TL, Zhou W, Robinson MO and Harrington L: Reconstitution of human telomerase activity in vitro. Curr Biol (1998) 8: 177-180.
29. Keith WN, Sarvesvaran J and Downey M: Analysis of telomerase RNA gene expression by in situ hybridization. Methods Mol Biol (2002) 191: 65-81.
30. Bilsland AE, Merron A, Vassaux G and Keith WN: Modulation of telomerase promoter tumor selectivity in the context of oncolytic adenoviruses. Cancer Res (2007) 67: 1299-1307.
31. Wirth T, Zender L, Schulte B, Mundt B, Plentz R, Rudolph KL, Manns M, Kubicka S and Kuhnel F: A telomerase-dependent con ditionally replicating adenovirus for selective treatment of cancer. Cancer Res (2003) 63: 3181-3188.
32. Lanson NA Jr, Friedlander PL, Schwarzenberger P, Kolls JK and Wang G: Replication of an adenoviral vector controlled by the human telomerase reverse transcriptase promoter causes tumor-selective tumor lysis. Cancer Res (2003) 63: 7936-7941.
33. Irving J, Wang Z, Powell S, O'Sullivan C, Mok M, Murphy B, Cardoza L, Lebkowski JS and Majumdar AS: Conditionally repli-cative adenovirus driven by the human telomerase promoter pro vides broad-spectrum antitumor activity without liver toxicity. Cancer Gene Ther (2004) 11: 174-185.
34. Kim E, Kim JH, Shin HY, Lee H, Yang JM, Kim J, Sohn JH, Kim H and Yun CO: Ad-mTERT-delta19, a conditional replication-competent adenovirus driven by the human telomerase promoter, selectively replicates in and elicits cytopathic effect in a cancer cell-specific manner. Hum Gene Ther (2003) 14: 1415-1428.
35. Huang TG, Savontaus MJ, Shinozaki K, Sauter BV and Woo SL: Telomerase-dependent oncolytic adenovirus for cancer treatment. Gene Ther (2003) 10: 1241-1247.
36. ZouW, Luo C, Zhang Z, Liu J, GuJ, Pei Z, Qian C and Liu X: A novel oncolytic adenovirus targeting to telomerase activity in tumor cells with potent. Oncogene (2004) 23: 457-464.
37. Kuppuswamy M, Spencer JF, Doronin K, Tollefson AE, Wold WS and Toth K: Oncolytic adenovirus that overproduces ADP and rep licates selectively in tumors due to hTERT promoter-regulated E4 gene expression. Gene Ther (2005) 12: 1608-1617.
38. Li Y, Yu DC, Chen Y, Amin P, Zhang H, Nguyen N and Henderson DR: A hepatocellular carcinoma-specific adenovirus variant, CV890, eliminates distant human liver tumors in combina tion with doxorubicin. Cancer Res (2001) 61: 6428-6436.
39. Kawashima T, Kagawa S, Kobayashi N, Shirakiya Y, Umeoka T, Teraishi F, Taki M, Kyo S, Tanaka N and Fujiwara T: Telomerase-specific replication-selective virotherapy for human cancer. Clin Cancer Res (2004) 10: 285-292.
40. Taki M, Kagawa S, Nishizaki M, Mizuguchi H, Hayakawa T, Kyo S, Nagai K, UrataY, Tanaka N and Fujiwara T: Enhanced oncol-ysis by a tropism-modified telomerase-specific replication-selective adenoviral agent OBP-405 (Telomelysin-RGD'). Oncogene (2005) 24: 3130-3140.
41. Hashimoto Y, Watanabe Y, Shirakiya Y, Uno F, Kagawa S, Kawamura H, Nagai K, Tanaka N, Kumon H, Urata Y and Fujiwara T: Establishment of biological and pharmacokinetic assays of telomerase-specific replication-selective adenovirus. Cancer Sci (2008) 99: 385-390.
42. Fujiwara T, Urata Y and Tanaka N: Telomerase-specific oncolytic virotherapy for human cancer with the hTERT promoter. Curr Cancer Drug Targets (2007) 7: 191-201.
43. Maehara Y, Oshiro T, Endo K, Baba H, Oda S, Ichiyoshi Y, Kohnoe S and Sugimachi K: Clinical significance of occult micro-metastasis lymph nodes from patients with early gastric cancer who died of recurrence. Surgery (1996) 119: 397-402.
44. Rivadeneira DE, Simmons RM, Christos PJ, Hanna K, Daly JM and Osborne MP: Predictive factors associated with axillary lymph node metastases in T1a and T1b breast carcinomas: analysis in more than 900 patients. J Am Coll Surg (2000) 191: 1-6.
45. Chang GJ, Rodriguez-Bigas MA, Skibber JM and Moyer VA: Lymph node evaluation and survival after curative resection of colon cancer: systematic review. J Natl Cancer Inst (2007) 99: 433-441.
46. Volpe CM, Koo J, Miloro SM, Driscoll DL, Nava HR and Douglass HO, Jr.: The effect of extended lymphadenectomy on survival in patients with gastric adenocarcinoma. J Am Coll Surg (1995) 181: 56-64.
47. Harrison LE, Karpeh MS and Brennan MF: Extended lymph adenectomy is associated with a survival benefit for node-negative gastric cancer. J Gastrointest Surg (1998) 2: 126-131.
48. Sasako M, Sano T, Yamamoto S, Kurokawa Y, Nashimoto A, Kurita A, Hiratsuka M, Tsujinaka T, Kinoshita T, Arai K, Yamamura Y and Okajima K: D2 lymphadenectomy alone or with para-aortic nodal dissection for gastric cancer. N Engl J Med (2008) 359: 453-462.
49. Gotoda T, Sasako M, Ono H, Katai H, Sano T and Shimoda T: Evaluation of the necessity for gastrectomy with lymph node dis section for patients with submucosal invasive gastric cancer. Br J Surg (2001) 88: 444-449.
50. Liu TC and Kirn D: Systemic efficacy with oncolytic virus therapeutics: clinical proof-of-concept and future directions. Cancer Res (2007) 67: 429-432.
51. Burton JB, Johnson M, Sato M, Koh SB, Mulholland DJ, Stout D, Chatziioannou AF, Phelps ME, Wu H and Wu L: Adenovirus-mediated gene expression imaging to directly detect sentinel lymph node metastasis of prostate cancer. Nat Med (2008) 14: 882-888.
52. Kishimoto H, Kojima T, Watanabe Y, Kagawa S, Fujiwara T, Uno F, Teraishi F, Kyo S, Mizuguchi H, Hashimoto Y, Urata Y, Tanaka N and Fujiwara T: In vivo imaging of lymph node metasta sis with telomerase-specific replication-selective adenovirus. Nat Med (2006) 12: 1213-1219.
53. Kurihara Y, Watanabe Y, Onimatsu H, Kojima T, Shirota T, Hatori M, Liu D, Kyo S, Mizuguchi H, Urata Y, Shintani S and Fujiwara T: Telomerase-specific virotheranostics for human head and neck cancer. Clin Cancer Res (2009) 15: 2335-2343.
54. Kojima T, Watanabe Y, Hashimoto Y, Kuroda S, Yamasaki Y, Yano S, Ouchi M, Tazawa H, Uno F, Kagawa S, Kyo S, Mizuguchi H, Urata Y, Tanaka N and Fujiwara T: In vivo biologi cal purging for lymph node metastasis of human colorectal cancer by telomerase-specific oncolytic virotherapy. Ann Surg (2010) 251: 1079-1086.
55. Kawabata K, Sakurai F, Koizumi N, Hayakawa T and Mizuguchi H: Adenovirus vector-mediated gene transfer into stem cells. Mol Pharm(2006)3: 95-103.
56. Burdelya LG, Krivokrysenko VI, Tallant TC, Strom E, Gleiberman AS, Gupta D, Kurnasov OV, Fort FL, Osterman AL, Didonato JA, Feinstein E and Gudkov AV: An agonist of toll-like receptor 5 has radioprotective activity in mouse and primate models. Science (2008) 320: 226-230.
57. Folkman J: Role of angiogenesis in tumor growth and metastasis. Semin Oncol (2002)29: 15-18.
58. Bentzen SM, Harari PM and Bernier J: Exploitable mechanisms for combining drugs with radiation: concepts, achievements and future directions. Nat Clin Pract Oncol (2007) 4: 172-180.
59. Bradley KA, Pollack IF, Reid JM, Adamson PC, Ames MM, Vezina G, Blaney S, Ivy P, Zhou T, Krailo M, Reaman G and Mehta MP: Motexafin gadolinium and involved field radiation ther apy for intrinsic pontine glioma of childhood: a Children's Oncology Group phase I study. Neuro Oncol (2008) 10: 752-758.
60. Hoskin P, Rojas A and Saunders M: Accelerated radiotherapy, carbogen, and nicotinamide (ARCON) in the treatment of advanced bladder cancer: mature results of a Phase II nonrandomized study. Int J Radiat Oncol Biol Phys (2009) 73: 1425-1431.
61. Kim CH, Park SJ and Lee SH: A targeted inhibition of DNA-dependent protein kinase sensitizes breast cancer cells following ionizing radiation. J Pharmacol Exp Ther (2002) 303: 753-759.
62. Tang X, Hui ZG, Cui XL, Garg R, Kastan MB and Xu B: A novel ATM-dependent pathway regulates protein phosphatase 1 in response to DNA damage. Mol Cell Biol (2008) 28: 2559-2566.
63. Shiloh Y: Ataxia-telangiectasia and the Nijmegen breakage syndrome: related disorders but genes apart. Annu Rev Genet (1997)31: 635-662.
64. Petrini JH: The Mre11 complex and ATM: collaborating to navi gate S phase. Curr Opin Cell Biol (2000) 12: 293-296.
65. Sturgeon CM and Roberge M: G2 checkpoint kinase inhibitors exert their radiosensitizing effects prior to the G2/M transition. Cell Cycle (2007) 6: 572-575.
66. D'Amours D and Jackson SP: The Mre11 complex: at the cross roads of dna repair and checkpoint signalling. Nat Rev Mol Cell Biol (2002)3: 317-327.
67. Carson CT, Schwartz RA, Stracker TH, Lilley CE, Lee DV and Weitzman MD: The Mre11 complex is required for ATM activation and the G2/M checkpoint. EMBO J (2003) 22: 6610-6620.
68. Theunissen JW, Kaplan Ml, Hunt PA, Williams BR, Ferguson DO, Alt FW and Petrini JH: Checkpoint failure and chromosomal insta bility without lymphomagenesis in Mre11 (ATLD1/ATLD1) mice. Mol Cell (2003) 12: 1511-1523.
69. Blackford AN and Grand RJ: Adenovirus E1B 55-kilodalton protein: multiple roles in viral infection and cell transformation. J Virol (2009) 83: 4000-4012.
70. Kuroda S, Fujiwara T, Shirakawa Y, Yamasaki Y, Yano S, Uno F, Tazawa H, Hashimoto Y, Watanabe Y, Noma K, Urata Y, Kagawa S and Fujiwara T: Telomerase-dependent oncolytic aden ovirus sensitizes human cancer cells to ionizing radiation via inhi bition of DNA repair machinery. Cancer Res (2010) 70: 9339-9348.
71. Hart LS, Yannone SM, Naczki C, Orlando JS, Waters SB, Akman SA, Chen DJ, Ornelles D and Koumenis C: The adenovi rus E4orf6 protein inhibits DNA double strand break repair and radiosensitizes human tumor cells in an E1B-55K-independent manner. J Biol Chem (2005) 280: 1474-1481.
72. Fidler IJ: Rationale and methods for the use of nude mice to study the biology and therapy of human cancer metastasis. Cancer Metastasis Rev (1986) 5: 29-49.
73. Fujiwara T, Tanaka N, Numunaitis JJ, Senzer NN, Tong A, Ichimaru D, Shelby SM, Hashimoto Y, Kawamura H and Urata Y: Phase I trial of intratumoral administration of OBP-301, a novel telomerase-specific oncolytic virus, in patients with advanced solid cancer: Evaluation of biodistribution and immune response. J Clin Oncol (2008) 26: 3572.
74. Nemunaitis J, Tong AW, Nemunaitis M, Senzer N, Phadke AP, Bedell C, Adams N, Zhang YA, Maples PB, Chen S, Pappen B, Burke J, Ichimaru D, Urata Y and Fujiwara T: A phase I study of telomerase-specific replication competent oncolytic adenovirus (telomelysin) for various solid tumors. Mol Ther (2010) 18: 429-434.
75. DeWeese TL, van der PH, Li S, Mikhak B, Drew R, Goemann M, Hamper U, DeJong R, Detorie N, Rodriguez R, Haulk T, DeMarzo AM, Piantadosi S, Yu DC, Chen Y, Henderson DR, Carducci MA, Nelson WG and Simons JW: A phase I trial of CV706, a replication-competent, PSA selective oncolytic adenovi rus, for the treatment of locally recurrent prostate cancer following radiation therapy. Cancer Res (2001) 61: 7464-7472.
76. Small EJ, Carducci MA, Burke JM, Rodriguez R, Fong L, van UL, Yu DC, Aimi J, Ando D, Working P, Kirn D and Wilding G: A Phase I Trial of Intravenous CG7870, a Replication-Selective, Prostate-Specific Antigen-Targeted Oncolytic Adenovirus, for the Treatment of Hormone-Refractory, Metastatic Prostate Cancer. Mol Ther (2006).
77. Fujiwara T, Kagawa S, Kishimoto H, Endo Y, Hioki M, Ikeda Y, Sakai R, Urata Y, Tanaka N and Fujiwara T: Enhanced antitumor efficacy of telomerase-selective oncolytic adenoviral agent OBP-401 with docetaxel: Preclinical evaluation of chemovirotherapy. Int J Cancer (2006) 119: 432-440.
78. Watanabe T, Hioki M, Fujiwara T, Nishizaki M, Kagawa S, Taki M, Kishimoto H, Endo Y, Urata Y, Tanaka N and Fujiwara T: Histone deacetylase inhibitor FR901228 enhances the antitumor effect of telomerase-specific replication-selective adenoviral agent OBP-301 in human lung cancer cells. Exp Cell Res (2006) 312: 256-265.
79. Liu D, KojimaT, Ouchi M, Kuroda S, Watanabe Y, Hashimoto Y, Onimatsu H, Urata Y and Fujiwara T: Preclinical evaluation of synergistic effect of telomerase-specific oncolytic virotherapy and gemcitabine for human lung cancer. Mol Cancer Ther (2009) 8: 980-987.
80. Fujiwara T, Tanaka N, KanazawaS, Ohtani S, Saijo Y, NukiwaT, Yoshimura K, Sato T, Eto Y, Chada S, Nakamura H and Kato H: Multicenter phase I study of repeated intratumoral delivery of aden oviral p53 in patients with advanced non-small-cell lung cancer. J Clin Oncol (2006) 24: 1689-1699.
81. Sakai R, Kagawa S, Yamasaki Y, KojimaT, Uno F, Hashimoto Y, Watanabe Y, Urata Y, Tanaka N and Fujiwara T: Preclinical eval uation of differentially targeting dual virotherapy for human solid cancer. Mol Cancer Ther (2010) 9: 1884-1893.